What is *Vaxxers* by Sarah Gilbert about?

*Vaxxers* chronicles the urgent development of the Oxford-AstraZeneca COVID-19 vaccine, co-authored by vaccinologists Sarah Gilbert and Catherine Green. It combines firsthand accounts of scientific breakthroughs, logistical hurdles, and personal challenges faced during the pandemic. The book demystifies vaccine safety protocols and addresses public skepticism, emphasizing transparency in combating misinformation.

Who should read *Vaxxers*?

This book appeals to readers interested in medical science, pandemic history, or vaccine development. It’s ideal for science enthusiasts seeking insider perspectives on COVID-19 research, educators discussing public health ethics, or anyone curious about rapid scientific innovation under global pressure.

Is *Vaxxers* worth reading?

Yes—*Vaxxers* humanizes vaccine science through candid storytelling, offering clarity on complex virology and debunking myths. Gilbert and Green balance technical details with relatable anecdotes, making it accessible for non-experts while providing rare insights into large-scale medical collaboration.

How did Sarah Gilbert and Catherine Green create the Oxford-AstraZeneca vaccine?

The team designed the vaccine using viral vector technology (ChAdOx1), adapting prior Ebola and MERS research. They navigated unprecedented timelines, securing regulatory approvals and manufacturing partnerships within months. The book details how preexisting frameworks enabled rapid adaptation to SARS-CoV-2.

What challenges did the authors face during vaccine development?

Key hurdles included: - Scaling production while maintaining quality control - Addressing public mistrust and politicization of science - Balancing media scrutiny with research demands - Coordinating global trials amid shifting infection rates

Does *Vaxxers* explain how vaccines are tested for safety?

Yes—the authors outline clinical trial phases, peer review processes, and real-time data monitoring. They emphasize rigorous safety checks, including independent oversight committees and post-rollout surveillance to detect rare side effects.

How does *Vaxxers* address vaccine hesitancy?

Gilbert and Green confront misinformation by transparently explaining vaccine ingredients (e.g., adenovirus vectors, spike proteins) and dismissing conspiracy theories. They share personal encounters with skeptics, advocating for empathy in public communication.

What personal stories do the authors share in *Vaxxers*?

Anecdotes include: - Green reassuring a vaccine-hesitant camper about ingredients - Gilbert juggling lab work with caring for triplets - Emotional whiplash from media praise and criticism - Sleep-deprived nights analyzing trial data

《疫苗的故事》摘要

莎拉·吉尔伯特

《疫苗的故事》摘要概述

揭秘牛津-阿斯利康疫苗的研发历程，记录了莎拉·吉尔伯特女爵士（Dame Sarah Gilbert）与凯瑟琳·格林（Catherine Green，获授大英帝国勋章）如何与大流行病赛跑。克里斯·埃文斯（Chris Evans）赞誉其为“引人入胜之作”，这本畅销书在揭露科学界最紧迫任务背后的感人故事时，也有力地驳斥了反疫苗谣言。

选择讲述方式

用不同学习方式探索《疫苗的故事》摘要

来自《疫苗的故事》的相同理念。选择适合你的声音、深度和节奏，随时切换。

第 1 章

From Lab Bench to Global Hope: The Race Against COVID-19

When the world ground to a halt in early 2020, a small team of scientists in Oxford were already racing against time. While politicians debated lockdowns and hospitals filled with patients gasping for breath, Sarah Gilbert and Catherine Green were leading a scientific revolution that would ultimately save millions of lives. Their Oxford-AstraZeneca vaccine-developed in record time yet without cutting corners-would become one of humanity's greatest scientific achievements during the pandemic. The story behind this vaccine isn't one of shadowy global elites or pharmaceutical profiteering, but of dedicated scientists working through sleepless nights, weekend shifts, and personal sacrifices. Named by Time magazine as "Heroes of the Year" in 2021, Gilbert and Green's work exemplifies how ordinary people can accomplish extraordinary feats when faced with unprecedented challenges. Their vaccine, deliberately priced at cost and requiring only standard refrigeration, would ultimately reach 172 countries, becoming truly "a vaccine for the world."

第 2 章

The Pandemic Threat Emerges: Disease X Becomes Reality

In January 2020, Sarah Gilbert noticed concerning reports on ProMedMail about an unusual pneumonia outbreak in Wuhan, China. As a vaccinology professor specializing in emerging pathogens, she recognized the potential danger, especially when reports suggested it might be "SARS-like." By January 3rd, what began as four cases had grown to forty-four, with eleven critically ill. Gilbert had spent years preparing for what experts called "Disease X"-an unknown pathogen that could trigger a devastating pandemic. Her team had developed a versatile vaccine platform called ChAdOx1, designed to be quickly adapted against new threats. This platform used a modified chimpanzee adenovirus that couldn't replicate in humans but could deliver genetic instructions teaching the body to recognize dangerous pathogens. The original SARS coronavirus in 2002-2003 had infected 8,000 people across 29 countries with a 10% mortality rate before being contained. MERS-CoV emerged in 2012, spreading from bats to camels to humans with an even higher fatality rate. Unlike SARS, MERS could spread through mildly symptomatic carriers, making containment more difficult. A 2015 outbreak in South Korea infected 186 people, killed 38, and required quarantining 6,000 people. When news of the mysterious illness in China emerged, Gilbert considered whether it might be a virus that infected animals at the market but couldn't spread between humans. If true, closing the market would contain the outbreak without needing a vaccine. But this assessment was based on incomplete information-the full picture was yet to emerge. Despite having prepared for this moment, Gilbert's team had struggled to secure adequate funding for their platform technology. When CEPI (Coalition for Epidemic Preparedness Innovations) requested proposals for technologies against "Disease X," they applied but weren't funded-reviewers doubted viral-vectored vaccines could be produced quickly enough during an outbreak. By early January 2020, with reports of SARS-like pneumonia emerging, Gilbert's team was reasonably well-positioned to respond. After discussing with colleague Tess Lambe, they decided to begin vaccine development as soon as the genome sequence became available. Though still theoretical, this was their chance to demonstrate ChAdOx1's capabilities-and if this truly was Disease X, moving quickly at every stage would be essential.

边听边看，每个词都清晰呈现

轻松跟读，《疫苗的故事》摘要中的每个词都会随音频实时高亮。

第 3 章

Designing a Vaccine in Record Time

As 2019 ended with celebrations and personal challenges, no one at Catherine Green's New Year's Eve party mentioned a new virus in Wuhan. By January 6th, she had returned to her dual roles at Oxford-managing the Clinical Biomanufacturing Facility (CBF) and researching at the Wellcome Centre for Human Genetics. The CBF is rare among universities-a Good Manufacturing Practice facility that produces clinical-grade vaccines for diseases that pharmaceutical companies typically ignore due to limited profit potential. Green's team of twenty-five scientists produces starting materials, manufactures vaccines, and handles testing and certification for clinical trials. When Gilbert asked if they could immediately begin producing vaccine starting materials, Green had to balance financial risks against urgency. The CBF operates like a small business within the university, needing to cover its 1.5 million annual costs by charging researchers who secure grants. Prioritizing this coronavirus project meant delaying other funded projects. Despite the financial uncertainty, Green agreed to proceed. They would make about 100ml of "seed stock" from which all clinical-grade vaccine batches would be derived. They decided to try both their rapid method and the classic method in parallel as backup. By January 27th, with the synthetic DNA delivered (containing about 100 billion dehydrated strands of spike protein code in what looked like an empty test tube), they abandoned their original plan to wait three weeks. Instead, they used pre-prepared material to immediately begin their first attempt at the rapid method. Green briefly escaped to Paris for her birthday at month's end, drinking cocktails in crowded bars and visiting museums, unaware that this would soon feel like another era entirely. When she returned on January 31st-the day the UK left the EU and recorded its first coronavirus cases-none of them realized they were entering a radically different world. The team wasn't "searching for" or "finding" a vaccine-that language misrepresents their work. Vaccines aren't discovered like hidden treasure; they're designed based on accumulated scientific knowledge, then carefully made and thoroughly tested according to strict regulations.

第 4 章

The Financial Gamble: Finding Money to Save Lives

When Green asked where the money was coming from in early March, Gilbert had no answer except "We're just going to have to do it anyway and work out the money later." From January through April, as they and the world grasped the enormity of the pandemic, securing funding became Gilbert's main preoccupation-the most likely reason they might fail to deliver a vaccine. The rigid structure of research contracts leaves no room for creativity or discovery. Obtaining funding normally takes about a year with success rates under one in three. Each funder has different application processes and rules about what they'll pay for. Academic research careers are unstable, with researchers on short-term contracts tied to specific grants, causing many excellent scientists to leave academia. In early 2020, Gilbert leveraged existing VaxHub funding to get started, but knew they needed much more. After the WHO declared a public health emergency on January 30, both CEPI and UKRI put out calls for COVID-19 research proposals. She applied to both in mid-February, asking for about 10% of the available funds. Throughout February and March, they continued working without guaranteed funding. The university even took the unprecedented step of underwriting the contract with Advent before funding was confirmed. Gilbert also spent time lobbying the government through the UK BioIndustry Association, explaining they could make a vaccine quickly but needed substantial funding. Just five weeks after CEPI's call for proposals, they received $350,000 for making and testing starting materials-though they were already halfway through this work. On March 10, Gilbert spoke to the government's Science and Technology Committee about their vaccine development and urgent funding needs. The next day, WHO declared COVID-19 a global pandemic. By late March, their money worries eased. Gilbert's bid for 2 million from UKRI succeeded, followed by 20 million (later 31 million) from the UK's new Vaccines Taskforce on April 21. There was no celebration, just relief that disaster had been averted. Now they could focus on the science.

从《疫苗的故事》摘要中收获更多

每日获取新洞见，探索 10 万+ 条课程内容
文字实时高亮，与音频同步
保存你的书库，在所有设备上随时访问

第 5 章

Manufacturing Miracles: From Lab to Clinical Trials

Making an adenovirus-vectored vaccine is like making bread, with five essential steps: First, create the starting material (like a sourdough starter) by growing cells and introducing the viral vector; second, use this to produce the required quantity in a clean room through careful cell culture expansion; third, purify the vaccine from unwanted cellular components using specialized filtration and chromatography techniques; fourth, fill into individual vials in a sterile environment under precise temperature and pressure controls; and finally, label, document, test, certify and distribute according to strict regulatory guidelines. Every manufacturing stage is governed by detailed protocols-even putting on protective clothing requires a nineteen-page document detailing the exact sequence of donning gowns, masks, gloves, and boots. Clean room workers must undergo rigorous semi-annual training on aseptic technique, contamination prevention, and emergency procedures. Some people who naturally shed more bacteria, known as "high shedders," simply can't work there as they pose too great a contamination risk. Filling vials requires proven sterility techniques through multiple test runs, with environmental monitoring systems constantly checking air quality, particle counts, and surface contamination. The team initiated rapid testing to dramatically reduce their timeline, implementing parallel processing and round-the-clock operations. Working closely with the UK's Medicines and Healthcare products Regulatory Agency (MHRA), they developed an expensive but much faster testing program, costing nearly triple the standard approach. They proceeded "at risk" by preparing documentation and labeling before test results came back, something rarely done in vaccine development. Through late nights, weekend work, and extraordinary support from testing partners and specialized biological material couriers, they reduced testing time from the standard three months to just over two weeks, establishing new benchmarks for rapid vaccine development. On April 21, they received final test results confirming product safety and quality specifications, and the next day their Qualified Person Richard Tarrant certified the batch after reviewing thousands of pages of documentation. The precious vaccine vials were carefully carried across the road to the clinical trial site, temperature-monitored every step of the way. They had gone from DNA construct to clinical trial in sixty-five days-an achievement that seasoned vaccine developers had deemed impossible when they started in February. Though exhausted from weeks of intense work with little sleep, they celebrated with socially distanced cake in the facility breakroom, feeling they'd accomplished something unprecedented in vaccine development history, even without knowing if the vaccine would ultimately prove effective in human trials.

第 6 章

Scaling Up: From Hundreds to Billions of Doses

Spring was arriving, but lockdown felt endless with rising case numbers and no end in sight. On April 30th, they received news that Oxford had partnered with AstraZeneca for large-scale manufacture and global distribution of their COVID-19 vaccine. This was crucial-while Green's team had lovingly hand-made hundreds of vials for trials, they couldn't possibly scale to the millions or billions needed if the vaccine proved effective. The partnership initially felt jarring. They were surprised by the choice of AstraZeneca, known for cancer medicines but not vaccines. They felt disconnected from high-level university decisions affecting their work and worried about profits from their efforts. The press release reassured them about non-profit operation during the pandemic and commitment to low-cost delivery to poorer countries, but their relationship with the project had shifted. By early May, they were exhausted from making vaccine batches, coordinating with Advent in Italy for additional production, dealing with regulators, and working on scale-up-all while facing PPE shortages and staff absences. AstraZeneca's immediate hands-on approach felt overwhelming at first, with constant requests for meetings, documentation and samples. The cultural differences were stark-they were essentially a "family-run pizzeria" doing everything themselves, while AstraZeneca was "Pizza Express" with global systems and specialized teams who used unfamiliar abbreviations. But their ambition was inspiring-they confidently spoke of "billions of doses" when the Oxford team's biggest achievement had been manually filling 500 vials. AstraZeneca immediately recognized the importance of their data showing the vaccine could be stored at normal refrigeration temperatures (2-8C) rather than -80C, which would allow distribution through existing global vaccination supply chains. Meanwhile, they continued smaller-scale production for clinical trials. Working with Advent in Italy was a highlight-they were similar in size to the CBF team and specialized in viral vector manufacture. Their team was particularly motivated as Italy had already been devastated by COVID-19. By early May, Advent had successfully produced 3,000 vials for expanding clinical trials. They faced an unexpected challenge when comparing vaccine concentrations between their batch and Advent's. Using different measurement methods, they found a twofold difference in concentration readings. After careful testing, they decided to err on the side of caution for the Phase II/III trials. This resulted in some volunteers receiving what was effectively a half-dose, which later led to the confusing efficacy findings (62%, 70% and 90%) reported in November 2020.

边听边看，每个词都清晰呈现

轻松跟读，《疫苗的故事》摘要中的每个词都会随音频实时高亮。

第 7 章

The Race Against Time: No Shortcuts to Safety

People often asked how they turned a ten-year process into one year without cutting corners. The answer lies in three key factors: their previous work, changes to funding approaches, and doing things in parallel rather than sequence. First, they weren't starting from scratch-they had years of experience with their ChAdOx1 platform technology, including work on other coronaviruses like MERS. This meant they knew their vaccine design before even seeing the SARS-CoV-2 genome. Second, funding cycles were enormously compressed. Rather than the usual years-long process of applying for successive tranches of funding, by April they had 20 million in government funding and AstraZeneca's support, followed by $1.2 billion from the US government's Operation Warp Speed. Third, they proceeded "at risk"-conducting parallel processes that would normally happen sequentially. They manufactured clinical-grade vaccine while still testing in animals. They prepared clinical trials before completing preclinical work. AstraZeneca manufactured millions of doses before knowing if the vaccine worked. The MHRA reviewed their data-over 500,000 pages-on a rolling basis rather than waiting until everything was complete. They didn't cut corners or take risks with safety-they still did every single step required for safe vaccine development. They simply eliminated the waiting time because every day counted as the pandemic claimed more lives. Thursday 23 April was the day they put their first vaccine shot into their first volunteer. Two volunteers, Elisa Granato and Edward O'Neill, received either the real vaccine or a placebo in a blinded study. Neither they nor the administering nurse knew which was which. After monitoring for an hour, they were free to go. This moment triggered mixed emotions: relief, optimism, gratitude, and nerves. Clinical trials have three phases: Phase I tests safety in small groups of healthy adults aged 18-55, monitoring for adverse events through health diaries and blood samples. Phase II expands to more people with wider age ranges, still screening for health conditions. Phase III includes thousands of people without pre-screening, focusing on whether the vaccine actually protects against disease. Designing their trials meant making difficult decisions with limited information. They considered challenge trials but ruled them out due to ethical concerns about exposing people to a poorly understood virus with no known treatment. Though UK lockdown reduced infection rates-good for public health but problematic for their trial timeline-they pushed forward with preparations, training nurses, creating information materials, and recruiting volunteers.

第 8 章

Facing the Public: Science in the Spotlight

The start of clinical trials thrust them into the public spotlight in unprecedented ways. Just three days after vaccinating their first volunteers, false claims spread rapidly across social media that participant Elisa Granato had died-completely untrue but worryingly credible given the heightened public anxiety. Elisa handled the situation with remarkable composure, posting on Twitter and doing a date-stamped BBC interview to prove she was alive and well. This incident highlighted how quickly misinformation could spread and potentially undermine public confidence in vaccine trials. The media attention became so intense and distracting that they implemented a comprehensive media blackout to focus on the critical work of safely vaccinating volunteers. Their rigorous monitoring protocol required volunteers to complete detailed daily health diaries for the first week, documenting even minor symptoms. Participants reported any health issues for a month and were obligated to report serious events for a full year. The follow-up schedule was demanding but essential: volunteers returned for check-ups and blood tests after 3, 7, 14, 28 and 56 days, allowing the team to meticulously study their immune response through antibody levels and T-cell responses. In June 2020, they received a confidential visit from Prince William, a pivotal moment for team morale. The day coincidentally aligned with a planned anti-vaccine protest targeting Green's building, though security had assessed it as low-risk. While protestors demonstrated outside with megaphones and placards, the prince conducted a thorough tour of their facilities-donning full PPE, visiting the specialized clean room where Green produces the vaccine, meeting trial volunteers at the mobile clinic, and engaging in detailed discussions with their lab team. Despite the unusual circumstances of socially distanced seating and mandatory masks, the prince demonstrated impressive knowledge of vaccine development and showed genuine interest in their work, providing an invaluable morale boost for the exhausted team. The scientists grappled with understanding the opposition to vaccines-interventions proven to be among the most safe, cost-effective public health measures in history, having saved millions of lives and prevented countless disabilities from polio to measles. While anti-vaccine activists represent a small but vocal minority, their impact becomes significant only when they successfully interfere with broader public vaccine acceptance. The team recognized that vaccine hesitancy was a distinct and more nuanced phenomenon-people naturally seeking to understand risks and benefits, requiring scientists to engage transparently with these legitimate concerns. The history of medical experimentation contains troubling examples that continue to fuel today's vaccine hesitancy, from the infamous Tuskegee experiment where African American men were deliberately left untreated for syphilis, to manufacturing errors like the 1955 Cutter incident where improperly inactivated polio vaccine caused paralysis in some recipients. Modern vaccine development has incorporated extensive safeguards learned from these historical mistakes. Advanced platform technologies like ChAdOx1 fundamentally eliminate risks of inadequate pathogen inactivation. Contemporary manufacturing processes include multiple layers of safety checks, from rigorous testing of raw materials to repeated contamination screening, batch testing, and independent quality verification at every stage of production.

从《疫苗的故事》摘要中收获更多

每日获取新洞见，探索 10 万+ 条课程内容
文字实时高亮，与音频同步
保存你的书库，在所有设备上随时访问

第 9 章

From Trial Results to Global Impact

On November 9, 2020, BioNTech and Pfizer announced their impressive phase III trial results-a moment of relief rather than competitive disappointment for the Oxford team. Their success proved vaccines against SARS-CoV-2 were possible. Moderna followed with similarly strong results a week later. The Oxford team's own efficacy results finally arrived on November 23, showing 70% overall efficacy, with a surprising 90% efficacy in the group that received a half-dose followed by a standard dose. The announcement day brought media interviews, a call with Prince William, and eventually a small celebration with champagne in coffee cups. Just seven months after their first volunteer was immunized, they had a working vaccine that could be stored at normal refrigerator temperatures-making it accessible worldwide. However, despite initial positive headlines, negative press soon followed, particularly from American commentators questioning their methods and results. The criticism intensified, with critics claiming they weren't transparent enough, were cherry-picking data, and that their half-dose results stemmed from a mistake. Even Anthony Fauci publicly questioned why anyone would choose their vaccine over others with higher reported efficacy. This criticism felt deeply unfair to Gilbert, as the important point-that they had developed a safe, effective vaccine against a devastating disease-was being lost. The team couldn't immediately address criticisms in detail because regulatory requirements forced them to announce results via press release before their full peer-reviewed paper could be published. When their Lancet paper was finally published in December 2020, it answered many criticisms but didn't silence critics who framed vaccine development as a competition with winners and losers. The UK approved their vaccine on December 30th, and rollout began January 4th, 2021, amid soaring case numbers and a new national lockdown. In February 2021, real-world effectiveness data showed the Oxford AstraZeneca vaccine was 94% effective in preventing hospitalization after one dose, compared to 85% for Pfizer. This data exceeded expectations as real-world effectiveness is typically lower than clinical trial efficacy. Despite this success and the improving pandemic situation in the UK, European skepticism persisted.

第 10 章

Looking Beyond COVID: Preparing for Disease Y

One year after beginning their vaccine journey, the team was making variant vaccines while still learning about the original virus. By early 2021, three variants of concern had emerged. While the Kent variant appeared more infectious, antibodies from the original vaccine still neutralized it. Their focus shifted to the more concerning South African and Brazilian variants. Though they were working on variant vaccines, the process was more streamlined. With AstraZeneca fully involved, the CBF only needed to make the initial starting materials while AstraZeneca handled manufacturing at scale. Clinical trials wouldn't need to be repeated entirely-similar to annual flu vaccines, they would likely conduct small Phase I/II trials to demonstrate immune response, while simultaneously producing millions of doses. Disease Y is inevitable. Epidemiologists have warned how wildlife trade and intensive farming create opportunities for animal viruses to jump to humans. Disease Y could be another coronavirus, an influenza strain, or one of the estimated 1.67 million unstudied viruses in the world. Even during the COVID pandemic, other dangerous pathogens continued circulating-avian flu, Crimean-Congo hemorrhagic fever, Ebola, MERS, Lassa fever, and Nipah virus. To better prepare for Disease Y, we must improve infrastructure, systems, and global cooperation. We need to train and retain the next generation of scientists through STEM education and apprenticeships while enabling basic research at universities. The UK has proven it can drive innovation, but people want to pay for the cherry (the vaccine) without funding the cake (underlying technology). International cooperation is essential-"no one is safe until we are all safe." The Covax scheme is a start, but vaccine-rich countries should donate 10% of their stocks to transmission hotspots for maximum global impact. The pandemic has spread misinformation alongside the virus, yet also driven interest in science. We need better scientific communication and more secure scientific careers to prioritize public engagement. The pandemic has painfully reminded us that a microscopic virus can devastate the world, while a vaccine from a small university city can save lives globally-powerful evidence that our biggest challenges and most powerful solutions are inherently global.

★★★★★

你已读完《疫苗的故事》摘要

“坚持使用 23 天了，我每天都会打开它。它现在已经成为我的日常习惯。”

jayallen

《疫苗的故事》摘要中的核心主题

vaccine platform technology
epidemic preparedness
clinical biomanufacturing
rapid scientific response
viral vector design

《疫苗的故事》摘要精选金句

Vaccines aren't discovered like hidden treasure; they're designed.
Academic research careers are unstable.
We're just going to have to do it anyway and work out the money later.
Named by Time magazine as "Heroes of the Year" in 2021.
This wasn't one of shadowy global elites or pharmaceutical profiteering.

《疫苗的故事》摘要中的人物

Sarah GilbertVaccinology professor and lead vaccine developer
Catherine GreenHead of the Clinical Biomanufacturing Facility
Tess LambeScientist and colleague of Sarah Gilbert

关于作者

Sarah Gilbert 是 Vaxxers 的作者，也是一位著名的疫苗学家，她在流行病应对方面的开创性工作塑造了全球公共卫生。作为牛津大学的疫苗学教授和 Vaccitech 的联合创始人，Gilbert 将数十年的病毒免疫学专业知识与现实世界的危机领导力相结合。

她的职业生涯亮点包括带头研发了牛津-阿斯利康（Oxford–AstraZeneca）新冠疫苗，该疫苗于 2020 年底获批，并已在全球范围内分发给超过 30 亿人。Gilbert 的研究重点是针对新兴病原体（特别是流感和新型冠状病毒）的疫苗设计，将学术严谨性与人道主义紧迫感融为一体。

她曾荣获阿尔伯特奖章（2021年）和阿斯图里亚斯亲王奖（2021年）等盛誉，巩固了她作为科学创新领军人物的地位。Vaxxers 将回忆录与科学见解相结合，提供了大流行期间疫苗研发的权威第一手记录。

这本书因其对医学伦理、全球协作以及科学快速进步对社会影响的深入浅出且严谨的探讨而广受赞誉。Gilbert 的工作持续影响着公共卫生政策，并激励着未来一代的研究人员。

下载《疫苗的故事》摘要

免费获取《疫苗的故事》摘要的 PDF 或 EPUB 版本。可打印或随时离线阅读。

用户还喜欢

Ben Goldacre

Sharyl Attkisson

Eula Biss

Laura Dodsworth

Carl Zimmer

Scott Gottlieb

Nicholas A. Christakis

World War C

Sanjay Gupta

关于《疫苗的故事》摘要的常见问题

发现更多

学习计划

Nature's Lethal Ambition

This plan offers a unique look at how humanity has harnessed nature's toxins for power, war, and status. It is ideal for history buffs, science enthusiasts, and true crime fans interested in the dark evolution of toxicology.

1 h 12 m•3 章节

学习计划

The Skeptic's Guide to Causal Genomics

This guide is essential for bioinformaticians and researchers who need to move beyond simple correlation to identify true disease drivers. It provides the critical toolkit necessary to navigate the complexities of TWAS and confounding variables in modern regulatory networks.

1 h 12 m•3 章节

学习计划

The Glass Revolution: From Sand to Super-Science

This plan explores how a simple material transformed human perception and global connectivity. It is ideal for history enthusiasts, science students, and curious minds interested in the intersection of material science and technological progress.

2 h•4 章节

学习计划

The Biology of Human Empire

This plan bridges the gap between evolutionary biology and historical geopolitics to explain why human societies rise and fall. It is ideal for history buffs, sociologists, and strategists looking to understand the primal drivers of power and systemic collapse.

1 h 30 m•3 章节

学习计划

The Science of Self-Sabotage

This plan is essential for high-achievers and chronic caretakers who feel stuck in repetitive patterns of failure or burnout. It offers a deep dive into the neurobiology of behavior, making it ideal for anyone looking to reclaim control over their choices and mental well-being.

30 m•3 章节

学习计划

The Smart Decade in Medicine

This learning plan explores the frontier where biology meets engineering, detailing the technologies redefining human health. It is essential for healthcare professionals, biotech investors, and tech enthusiasts looking to understand the next decade of medical innovation.

1 h 24 m•4 章节

学习计划

Becoming Supernatural: The Science of Self-Transformation

This learning plan bridges the gap between ancient wisdom and modern science for those seeking radical personal change. It is ideal for individuals looking to transcend their current limitations by mastering the intersection of neuroscience, biology, and mindfulness.

1 h 30 m•3 章节

学习计划

The Rise of Sapiens

This plan offers a profound look at the cognitive and structural shifts that defined humanity's trajectory. It is ideal for history enthusiasts and curious minds seeking to understand how collective beliefs and scientific breakthroughs shaped the modern world.

1 h 12 m•3 章节

由哥伦比亚大学校友创建源自旧金山

BeFreed 汇聚全球求知若渴的学习者

4.7

平均评分

7,840+ 条 App 评分

BeFreed Community

"Instead of endless scrolling, I just hit play on BeFreed. It saves me so much time."

@Moemenn

"I never knew where to start with nonfiction—BeFreed’s book lists turned into podcasts gave me a clear path."

@Chloe, Solo founder, LA

117

"Perfect balance between learning and entertainment. Finished ‘Thinking, Fast and Slow’ on my commute this week."

@Raaaaaachelw

"Crazy how much I learned while walking the dog. BeFreed = small habits → big gains."

@Matt, YC alum

108

"Reading used to feel like a chore. Now it’s just part of my lifestyle."

@Erin, Investment Banking Associate , NYC

254

"Feels effortless compared to reading. I’ve finished 6 books this month already."

@djmikemoore

"BeFreed turned my guilty doomscrolling into something that feels productive and inspiring."

@Pitiful

4.5K

"BeFreed turned my commute into learning time. 20-min podcasts are perfect for finishing books I never had time for."

@SofiaP

"BeFreed replaced my podcast queue. Imagine Spotify for books — that’s it. 🙌"

@Jaded_Falcon

201

"It is great for me to learn something from the book without reading it."

@OojasSalunke

"The themed book list podcasts help me connect ideas across authors—like a guided audio journey."

@Leo, Law Student, UPenn

483

"Makes me feel smarter every time before going to work"

@Cashflowbubu

查看更多网络上关于 BeFreed 的讨论

由哥伦比亚大学校友创建源自旧金山

BeFreed 汇聚全球求知若渴的学习者

4.7

平均评分

7,840+ 条 App 评分

BeFreed Community

"Instead of endless scrolling, I just hit play on BeFreed. It saves me so much time."

@Moemenn

"I never knew where to start with nonfiction—BeFreed’s book lists turned into podcasts gave me a clear path."

@Chloe, Solo founder, LA

117

"Perfect balance between learning and entertainment. Finished ‘Thinking, Fast and Slow’ on my commute this week."

@Raaaaaachelw

"Crazy how much I learned while walking the dog. BeFreed = small habits → big gains."

@Matt, YC alum

108

"Reading used to feel like a chore. Now it’s just part of my lifestyle."

@Erin, Investment Banking Associate , NYC

254

"Feels effortless compared to reading. I’ve finished 6 books this month already."

@djmikemoore

"BeFreed turned my guilty doomscrolling into something that feels productive and inspiring."

@Pitiful

4.5K

"BeFreed turned my commute into learning time. 20-min podcasts are perfect for finishing books I never had time for."

@SofiaP

"BeFreed replaced my podcast queue. Imagine Spotify for books — that’s it. 🙌"

@Jaded_Falcon

201

"It is great for me to learn something from the book without reading it."

@OojasSalunke

"The themed book list podcasts help me connect ideas across authors—like a guided audio journey."

@Leo, Law Student, UPenn

483

"Makes me feel smarter every time before going to work"

@Cashflowbubu

"Instead of endless scrolling, I just hit play on BeFreed. It saves me so much time."

@Moemenn

"I never knew where to start with nonfiction—BeFreed’s book lists turned into podcasts gave me a clear path."

@Chloe, Solo founder, LA

117

"Perfect balance between learning and entertainment. Finished ‘Thinking, Fast and Slow’ on my commute this week."

@Raaaaaachelw

"Crazy how much I learned while walking the dog. BeFreed = small habits → big gains."

@Matt, YC alum

108

"Reading used to feel like a chore. Now it’s just part of my lifestyle."

@Erin, Investment Banking Associate , NYC

254

"Feels effortless compared to reading. I’ve finished 6 books this month already."

@djmikemoore

"BeFreed turned my guilty doomscrolling into something that feels productive and inspiring."

@Pitiful

4.5K

"BeFreed turned my commute into learning time. 20-min podcasts are perfect for finishing books I never had time for."

@SofiaP

"BeFreed replaced my podcast queue. Imagine Spotify for books — that’s it. 🙌"

@Jaded_Falcon

201

"It is great for me to learn something from the book without reading it."

@OojasSalunke

"The themed book list podcasts help me connect ideas across authors—like a guided audio journey."

@Leo, Law Student, UPenn

483

"Makes me feel smarter every time before going to work"

@Cashflowbubu

"Instead of endless scrolling, I just hit play on BeFreed. It saves me so much time."

@Moemenn

"I never knew where to start with nonfiction—BeFreed’s book lists turned into podcasts gave me a clear path."

@Chloe, Solo founder, LA

117

"Perfect balance between learning and entertainment. Finished ‘Thinking, Fast and Slow’ on my commute this week."

@Raaaaaachelw

"Crazy how much I learned while walking the dog. BeFreed = small habits → big gains."

@Matt, YC alum

108

"Reading used to feel like a chore. Now it’s just part of my lifestyle."

@Erin, Investment Banking Associate , NYC

254

"Feels effortless compared to reading. I’ve finished 6 books this month already."

@djmikemoore

"BeFreed turned my guilty doomscrolling into something that feels productive and inspiring."

@Pitiful

4.5K

"BeFreed turned my commute into learning time. 20-min podcasts are perfect for finishing books I never had time for."

@SofiaP

"BeFreed replaced my podcast queue. Imagine Spotify for books — that’s it. 🙌"

@Jaded_Falcon

201

"It is great for me to learn something from the book without reading it."

@OojasSalunke

"The themed book list podcasts help me connect ideas across authors—like a guided audio journey."

@Leo, Law Student, UPenn

483

"Makes me feel smarter every time before going to work"

@Cashflowbubu

查看更多网络上关于 BeFreed 的讨论

开启你的学习之旅，就是现在

第 8 章

《疫苗的故事》摘要

《疫苗的故事》摘要概述

用不同学习方式探索《疫苗的故事》摘要

From Lab Bench to Global Hope: The Race Against COVID-19

The Pandemic Threat Emerges: Disease X Becomes Reality

边听边看，每个词都清晰呈现

Designing a Vaccine in Record Time

The Financial Gamble: Finding Money to Save Lives

从《疫苗的故事》摘要中收获更多

Manufacturing Miracles: From Lab to Clinical Trials

Scaling Up: From Hundreds to Billions of Doses

边听边看，每个词都清晰呈现

The Race Against Time: No Shortcuts to Safety

Facing the Public: Science in the Spotlight

从《疫苗的故事》摘要中收获更多

From Trial Results to Global Impact

Looking Beyond COVID: Preparing for Disease Y

你已读完《疫苗的故事》摘要

《疫苗的故事》摘要中的核心主题

《疫苗的故事》摘要精选金句

《疫苗的故事》摘要中的人物

关于作者

下载《疫苗的故事》摘要

用户还喜欢

关于《疫苗的故事》摘要的常见问题

What is Vaxxers by Sarah Gilbert about?

Who should read Vaxxers?

Is Vaxxers worth reading?

How did Sarah Gilbert and Catherine Green create the Oxford-AstraZeneca vaccine?

发现更多

BeFreed 汇聚全球求知若渴的学习者

BeFreed 汇聚全球求知若渴的学习者

用不同学习方式探索《疫苗的故事》摘要

From Lab Bench to Global Hope: The Race Against COVID-19

The Pandemic Threat Emerges: Disease X Becomes Reality

边听边看，每个词都清晰呈现

Designing a Vaccine in Record Time

The Financial Gamble: Finding Money to Save Lives

从《疫苗的故事》摘要中收获更多

Manufacturing Miracles: From Lab to Clinical Trials

Scaling Up: From Hundreds to Billions of Doses

边听边看，每个词都清晰呈现

The Race Against Time: No Shortcuts to Safety

Facing the Public: Science in the Spotlight

从《疫苗的故事》摘要中收获更多

From Trial Results to Global Impact

Looking Beyond COVID: Preparing for Disease Y

你已读完《疫苗的故事》摘要

用户还喜欢

发现更多